Oramed Pharmaceuticals Inc. ORMP
Set alert
4.00 USD -0.11 -2.68%
At close · Nov 2
4.00 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
4.00 Day range 4.11
2.09 52-week range 5.47
- YTD
- +40.35%
- 1 year
- +67.36%
- Open
- 4.11
- Prev close
- 4.11
- Mkt cap
- 166.39M
- Vol
- 97.26K
- Avg vol
- 178.58K
- EPS
- 4.13
- P/E
- 0.97
- Div yield
- 5.91%
More statistics
- Low
- 4.00
- High
- 4.11
- Forward P/E
- -29.75
- Beta
- 1.77
- Short ratio
- 2.60
- Inst. own
- 17.52%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.38
- 200-d avg
- 2.43
- 1y target
- 3.25
3M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Analyst view
Consensus: none
Price target (mean) 3.25
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.07 | -0.07 – -0.07 | 0.33 | -121.2% | 0 | 0.0% | 1 |
| Next quarter | -0.05 | -0.05 – -0.05 | 0.00 | 0.0% | 500.00K | 0.0% | 1 |
| Current year | 0.17 | 0.17 – 0.17 | 0.14 | +21.4% | 0 | -100.0% | 1 |
| Next year | -0.26 | -0.26 – -0.26 | 0.17 | -252.9% | 1.00M | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 20, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 17, 2023 | Canaccord Genuity | Maintained | Hold | Hold |
| Jan 17, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 12, 2023 | Canaccord Genuity | Downgrade | Buy | Hold |
| May 16, 2022 | Aegis Capital | Maintained | — | Buy |
| Feb 18, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 30, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 29, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 2, 2021 | Aegis Capital | Maintained | — | Buy |
| Jul 29, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Jun 8, 2021 | Aegis Capital | Maintained | — | Buy |
| Apr 20, 2021 | Canaccord Genuity | Initiated | — | Buy |
| Feb 9, 2021 | National Securities Corporation | Initiated | — | Buy |
| Jan 27, 2021 | Aegis Capital | Maintained | — | Buy |
| Jul 13, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jun 22, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 11, 2019 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 19, 2015 | FBR Capital | Initiated | — | Outperform |
| Oct 1, 2015 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 4, 2013 | Aegis Capital | Initiated | — | Buy |